Lupin Shares Phase 1 Data on LNP8701 at ASCO 2026

Lupin Limited announced that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The abstract details findings from an ongoing first-in-human study of LNP8701 in patients with metastatic solid tumors. Results indicate LNP8701 was well tolerated with desirable safety, pharmacokinetics profile, and favorable anti-tumor activity. Preliminary efficacy showed two patients completed 12 cycles and one patient completed 14 cycles with stable disease. Lupin will continue to study LNP8701's efficacy in its Phase 1b trial in India, exploring its potential as both monotherapy and combination therapy for solid tumors.